Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about SPTX, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| SPT-300 | Major Depressive Disorder (MDD) | Phase 2 · NCT07065240 | Recruiting |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
SPTX holds $290.4M in cash and short-term investments (as of Sep 30, 2026) and burns about $24.4M/quarter from operations, an estimated runway of 35.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 0 · Low
Based on our current operating plans, we believe that our existing cash, cash equivalents and investments will be sufficient to fund our operating expenses and capital expenditure requirements into 2029.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when SPTX files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| PureTech Health plc 10% owner |
Insider | 16,685,013 | 31.17% | 2026-06-30 |
| ARCH Venture Partners XII, LLC 10% owner |
Insider | 6,294,951 | 11.76% | 2026-05-04 |
| ARCH Venture Fund XII, L.P. | 5%+ holder (13D) | 6,294,951 | 11.76% | 2026-05-04 |
| Arch Venture Management, Llc | Institution (13F) | 6,294,951 | 11.76% | 2026-09-30 |
| General Atlantic (SP), L.P. Director, 10% owner |
Insider | 6,101,582 | 11.40% | 2026-05-04 |
| GAP Coinvestments CDA, L.P. Director, 10% owner Includes shares also reported by General Atlantic (SP), L.P., counted once |
Insider | 6,101,582 | 11.40% | 2026-05-04 |
| General Atlantic, L.P. | Institution (13G, 5%+) | 6,101,582 | 11.40% | 2026-05-04 |
| Sofinnova Investments, Inc. | Institution (13F) | 3,564,871 | 6.66% | 2026-09-30 |
| Steven M Paul Director · +991,192 options |
Insider | 3,516,718 | 6.57% | 2026-06-30 |
| THE GOLDMAN SACHS GROUP, INC. | Institution (13G, 5%+) | 2,791,814 | 5.22% | 2026-05-06 |
| James Healy Director |
Insider | 2,731,538 | 5.10% | 2026-05-04 |
| Trv Gp VI, LLC | Institution (13F) | 2,061,222 | 3.85% | 2026-09-30 |
Share count 53,530,550 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-09-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-11-10 filed 2026-11-13 |
Zohar Daphne |
Gift (G) | 100,000 | – | 1,094,001 |
| 2026-11-03 filed 2026-11-04 |
Torres Denice |
Purchase (P) | 5,000 | $19.87 | 5,000 |
| 2026-06-22 filed 2026-06-24 |
HOMBACH ROBERT J. |
Purchase (P) | 13,000 | $18.14 | 13,000 |
| 2026-05-04 filed 2026-05-06 |
PureTech Health plc |
Conversion (C) | 3,031,578 | – | – |
| 2026-05-04 filed 2026-05-06 |
PureTech Health plc |
Conversion (C) | 12,736,014 | – | 13,038,493 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for SPTX and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →